Podcasts about global neurology academy

CME credits: 1.00 Valid until: 17-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/clinical-pearls-in-recognizing-rett-syndrome-early-signs-and-diagnosis/57130/ This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

CME credits: 1.00 Valid until: 17-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/clinical-pearls-in-transition-supporting-patients-and-families-into-adulthood/57136/ This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

CME credits: 1.00 Valid until: 17-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/transitioning-to-adult-care-in-rett-syndrome-navigating-challenges/57135/ This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

CME credits: 1.00 Valid until: 17-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/clinical-pearls-in-adult-rett-syndrome-care-supporting-long-term-needs/57134/ This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

CME credits: 1.00 Valid until: 17-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/managing-rett-syndrome-building-a-multidisciplinary-care-approach/57133/ This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

CME credits: 1.00 Valid until: 17-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/clinical-pearls-in-rett-syndrome-management-practical-approaches-to-multidisciplinary-care/57132/ This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

CME credits: 1.00 Valid until: 17-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/managing-rett-syndrome-building-a-multidisciplinary-care-approach/57131/ This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

CME credits: 1.00 Valid until: 17-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-rett-syndrome-a-lifespan-approach-to-clinical-recognition/57129/ This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.

CME credits: 0.25 Valid until: 15-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/mechanism-to-match-choosing-the-right-vmat2-strategy-for-the-patient/54717/ This Podcast Plus discussion reviews how treatment for tardive dyskinesia can be individualized based on patient-specific goals and pharmacologic considerations. The program examines clinically relevant differences among VMAT2 inhibitors, including factors such as speed of response, durability, tolerability, and regimen simplicity. It also addresses treatment selection in the setting of polypharmacy, with attention to CYP2D6 and CYP3A4 interactions, dose limitations, titration, and practical issues such as insurance access. In addition, the discussion highlights follow-up considerations after treatment initiation, including assessment of response, tolerability, and patient satisfaction, to support ongoing management decisions in clinical practice.=

CME credits: 1.00 Valid until: 13-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/moving-beyond-sleep-the-broader-connection-between-the-orexin-system-and-psychiatric-disorders/48749/ Sleep and psychiatric disorders are often managed separately in clinical practice, leaving key biological mechanisms unaddressed and contributing to recurrent cycles of relapse. Overlapping factors, including orexin-driven arousal mechanisms, REM sleep abnormalities, limited use of validated screening tools, and incomplete differential diagnoses for hypersomnia, can further impair quality of life and outcomes. This broadcast replay will help improve clinicians' understanding of the biological link between sleep regulation and mood dysregulation, better known as the orexin system, to support a shift from fragmented, symptom-based management to integrated, mechanism-driven care.=

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Zarazuela Zolkipli-Cunningham, MBChB, MRCP Guest: Oscar H. (Hank) Mayer, MD Thymidine kinase 2 deficiency (TK2d) is a rare mitochondrial myopathy that can involve multiple organ systems, requiring care from different specialties. Given that need for multidisciplinary coordination, Dr. Charles Turck speaks with Drs. Hank Mayer and Zuela Zolkipli-Cunningham to learn how we can improve communication and collaboration across the care team throughout the diagnostic and management journey. Coming to us from the Children's Hospital of Philadelphia, Dr. Mayer is the Director of the Pulmonary Function Laboratory, and Dr. Zolkipli-Cunningham is the Director of Clinical Research in the Mitochondrial Medicine Frontier Program.

CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/not-all-vmat2s-are-the-same-understanding-the-pkpd-differences/56645/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/subtle-vs-syndromic-distinguishing-td-from-other-dimds-in-the-neuro-clinic/56642/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-15-minute-med-check-making-aims-and-td-screening-routine-in-psychiatry/56643/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/closing-the-gap-equity-disparities-and-access-to-td-diagnosis-and-care/56644/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/vmat2-in-the-real-world-recently-presented-pro-data-that-should-change-td-practice/56650/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-eps-to-personalized-td-treatment-matching-vmat2-moa-to-the-patient/56646/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/treating-the-complex-patient-td-management-in-older-adults-and-medically-fragile-populations/56647/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/shared-decisions-real-patients-patient-centered-td-and-antipsychotic-strategies/56648/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-evidence-to-everyday-practice-using-real-world-data-to-refine-td-algorithms/56649/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/when-movements-steal-lives-td-burden-stigma-and-the-therapeutic-alliance/56641/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Bethany Lussier, MD Patients often present with respiratory symptoms that don't quite align with typical pulmonary findings. So what clues should raise our suspicion that something beyond primary lung disease might be driving their condition? Joining Dr. Charles Turck to talk about the pulmonologist's role in identifying respiratory manifestations of thymidine kinase 2 deficiency (TK2d) is Dr. Bethany Lussier. She shares the hallmark features to look out for, like orthopnea and hypoventilation, as well as best practices for using pulmonary function testing and inspiratory pressure measures to distinguish muscle weakness from primary lung disease. Dr. Lussier is an Associate Professor of Internal Medicine at UT Southwestern Medical Center in Dallas, where she's also a member of the Division of Pulmonary and Critical Care Medicine.

Host: Alexandria May, PharmD, BCPS Guest: Kaitlin Batley, MD Fatigue and muscle weakness may seem routine, but when do they signal an underlying condition like thymidine kinase 2 deficiency (TK2d)? To find out, Dr. Alexandria May speaks with Dr. Kaitlin Batley, Director of the Pediatric Neuromuscular Program at Children's Health and an Assistant Professor of Pediatrics and Neurology at UT Southwestern Medical Center. They discuss how multisystem involvement can help distinguish TK2d from more common neuromuscular disorders and how we can achieve diagnostic clarity through advanced genetic testing, metabolic evaluation, and muscle biopsy.

CME credits: 0.50 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/fxia-remix-keeping-the-flow-without-missing-a-beat/54142/ Can an antithrombotic meaningfully reduce the risk of recurrent ischemic stroke without increasing major bleeding? Drs. Mike Sharma, Ashkan Shoamanesh, and Brian Mac Grory explore the science behind factor XIa inhibition and its potential to decouple thrombosis from hemostasis. The panel reviews pivotal OCEANIC-STROKE results presented at ISC 2026, highlighting a 26% relative risk reduction in ischemic stroke without an observed increase in ISTH major bleeding. They examine outcomes across stroke subtypes and place these results in context with other agents in development, such as milvexian and abelacimab. This conversation considers whether factor XI inhibition may alter long-standing assumptions about the tradeoff between efficacy and safety in secondary stroke prevention.=

Guest: Henry Kaminski, MD Myasthenia gravis is an unpredictable condition, with symptoms and treatment responses that can vary widely from one patient to the next. Tune in to hear Dr. Henry Kaminski explain how to navigate this variability and make thoughtful, individualized treatment decisions. Dr. Kaminski is the Meta A. Neumann Professor of the Department of Neurology at The George Washington University School of Medicine and Health Sciences in Washington.

CME credits: 1.00 Valid until: 30-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/emerging-focus-in-naion-sharpening-diagnostic-precision-for-tomorrows-treatments/49222/ This program addresses critical practice gaps in the evaluation and management of non-arteritic anterior ischemic optic neuropathy (NAION). Faculty will review acute ischemic pathophysiology, diagnostic variability, and structured approaches to improve diagnostic accuracy and readiness for clinical trials. Through case-based discussions, participants will learn how to identify key mimickers (eg, optic neuritis, AION) through targeted testing, apply evidence-based evaluation pathways, improve documentation practices, and recognize referral scenarios.The program will also highlight the impact of systemic risk factors, including GLP-1 receptor agonists, and provide the latest data on investigational agents like cenegermin and privosegtor. Designed for neuro-ophthalmologists, ophthalmologists, and neurologists, this activity supports enhanced diagnostic precision, informed patient counseling, and preparation for emerging NAION therapies.=

Host: Brian P. McDonough, MD, FAAFP Guest: Austin Larson, MD Emerging research on thymidine kinase 2 deficiency (TK2d) provides new insights into its global genetic prevalence and variability across genetic ancestries. By combining clinical literature with large genomic databases, investigators estimated disease incidence using carrier frequency under Hardy-Weinberg assumptions, uncovering significant differences between populations and key pathogenic variants. Joining Dr. Brian McDonough to discuss the findings and their implications for improving diagnostic accuracy and refining genetic testing strategies is Dr. Austin Larson. He's an Associate Professor of Pediatric Clinical Genetics and Metabolism at the University of Colorado Anschutz, and he presented these findings at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference.

Guest: Elizabeth Wilson, MD At the 2026 American Academy of Neurology (AAN) Annual Meeting, experts are sharing the latest developments in pediatric multiple sclerosis (MS). Dr. Elizabeth Wilson is here to share insights on how new adult MS research, neuro-ophthalmology collaboration, and emerging clinical data are shaping the future of care. Dr. Wilson is the Director of the Multiple Sclerosis and Neuroimmunology Center at Cincinnati Children's Hospital.

Guest: Elizabeth Wilson, MD At the 2026 American Academy of Neurology (AAN) Annual Meeting, experts are sharing the latest developments in pediatric multiple sclerosis (MS). Dr. Elizabeth Wilson is here to share insights on how new adult MS research, neuro-ophthalmology collaboration, and emerging clinical data are shaping the future of care. Dr. Wilson is the Director of the Multiple Sclerosis and Neuroimmunology Center at Cincinnati Children's Hospital.

Guest: Jennifer Yang, MD Emerging evidence shows that children with multiple sclerosis exhibit accelerated biological aging. Learn more about the potential implications with Dr. Jennifer Yang, who spoke about this topic at the 2026 ACTRIMS Forum. She's an Assistant Professor of Neurosciences at the UC San Diego School of Medicine and the Division of Pediatric Neurology at Rady Children's Hospital.

Guest: Adil Harroud, MD Guest: Dylan Hamitouche Host: Ryan Quigley Multimodal aging signatures are reshaping our understanding of progression and prognosis in multiple sclerosis (MS). Host Ryan Quigley sits down with Dr. Adil Harroud and Mr. Dylan Hamitouche to learn more about implications for the future of risk stratification and personalized treatment in MS, a topic they presented on at the 2026 ACTRIMS Forum. Dr. Harroud is a neurologist and the co-leader of the Neuroimmunology Diseases Research Group at the Montreal Neurological Institute at McGill University. Mr. Hamitouche is a medical student at McGill University.

Guest: Jennifer Yang, MD Emerging evidence shows that children with multiple sclerosis exhibit accelerated biological aging. Learn more about the potential implications with Dr. Jennifer Yang, who spoke about this topic at the 2026 ACTRIMS Forum. She's an Assistant Professor of Neurosciences at the UC San Diego School of Medicine and the Division of Pediatric Neurology at Rady Children's Hospital.

Guest: Raphael Schneider, MD, PhD, FRCPC, CIP Multiplex proteomic biomarker panels are redefining how we understand and monitor multiple sclerosis (MS) by capturing interconnected pathways in a single sample. Hear from Dr. Raphael Schneider as he explores how these tools could inform prognosis, risk stratification, and clinical trial design, which he spoke about at the 2026 ACTRIMS Forum. Dr. Schneider is a neurologist and researcher at the BARLO MS Centre at St. Michael's Hospital as well as an Assistant Professor and the Elizabeth S. Barford Early Career Professor in Multiple Sclerosis in the Department of Medicine at the University of Toronto.

Guest: Raphael Schneider, MD, PhD, FRCPC, CIP Multiplex proteomic biomarker panels are redefining how we understand and monitor multiple sclerosis (MS) by capturing interconnected pathways in a single sample. Hear from Dr. Raphael Schneider as he explores how these tools could inform prognosis, risk stratification, and clinical trial design, which he spoke about at the 2026 ACTRIMS Forum. Dr. Schneider is a neurologist and researcher at the BARLO MS Centre at St. Michael's Hospital as well as an Assistant Professor and the Elizabeth S. Barford Early Career Professor in Multiple Sclerosis in the Department of Medicine at the University of Toronto.

Guest: Adil Harroud, MD Guest: Dylan Hamitouche Host: Ryan Quigley Multimodal aging signatures are reshaping our understanding of progression and prognosis in multiple sclerosis (MS). Host Ryan Quigley sits down with Dr. Adil Harroud and Mr. Dylan Hamitouche to learn more about implications for the future of risk stratification and personalized treatment in MS, a topic they presented on at the 2026 ACTRIMS Forum. Dr. Harroud is a neurologist and the co-leader of the Neuroimmunology Diseases Research Group at the Montreal Neurological Institute at McGill University. Mr. Hamitouche is a medical student at McGill University.

Host: Hallie Blevins, PhD For patients with multiple sclerosis (MS), cognitive impairment can quietly erode independence and quality of life. In this AudioAbstract, Dr. Hallie Blevins discusses a head-to-head comparison of cognitive training, aerobic exercise, and a combined approach and explores how we can better support cognition in these patients.

Host: Jerome Lisk, MD, MBA, M.S., FAAN Guest: Michael Salvatore, PhD Guest: Vicki Nejtek-Salvatore, PhD Translational research is reshaping the way we understand, detect, and manage Parkinson's disease. To learn more about how current research efforts are uncovering early biomarkers and redefining intervention strategies, Dr. Jerome Lisk sits down with Dr. Michael Salvatore and Dr. Vicki Nejtek-Salvatore, professors at University of North Texas Health Science Center in Fort Worth and co-founders of the Parkinson Discovery Institute in Fort Worth, Texas.

CME credits: 1.00 Valid until: 19-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/new-pathways-in-the-treatment-of-dmd/48924/ The Duchenne muscular dystrophy (DMD) treatment landscape continues to evolve, with promising therapies emerging from new insights into disease biology. This activity explores the role of aberrant histone deacetylase (HDAC) activity in DMD pathophysiology, including its impact on inflammation, muscle degeneration, adipogenesis, and fibrosis. You'll review the latest clinical trial data and real-world evidence for novel therapies and understand where they may fit within complex, existing treatment regimens. Through practical case scenarios, the program highlights how to integrate new approaches into polypharmacy strategies. Stay ahead of the science and get ready to apply it.=

CME credits: 1.00 Valid until: 07-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-the-role-for-corticosteroids-within-the-evolving-dmd-treatment-landscape/37232/ Corticosteroids remain a cornerstone in Duchenne muscular dystrophy (DMD) management, but evolving therapies demand a more nuanced approach. This case-based activity explores how to proactively monitor and manage corticosteroid-associated side effects through interdisciplinary care coordination. Strengthen your care strategy as the DMD treatment landscape continues to shift.=

CME credits: 0.25 Valid until: 30-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/are-all-vmat2s-the-same-data-driven-treatment-decisions-for-tardive-dyskinesia/36174/ Tardive Dyskinesia (TD) is an involuntary movement disorder that can develop as a side effect of taking antipsychotic and other medications. Currently there are 2 FDA approved VMAT2 inhibitors for treating TD. Join Drs. Cristoph U. Correll and Jonathan M. Meyer for this expert discussion on the most recent data presented at the Psych Congress 2025 in San Diego on VMAT2 inhibitors for the treatment of TD.=

CME credits: 0.50 Valid until: 29-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/mechanism-driven-gmg-therapy-fcrn-antagonists-and-the-rise-of-precision-neurology/36277/ This Clinical Countdown addresses key challenges in diagnosing and managing generalized myasthenia gravis (gMG), with a focus on FcRn antagonists. Drs. Edmundson and Goyal review diagnostic challenges in gMG, along with the mechanism of FcRn blockade and how it compares to traditional therapies such as corticosteroids, IVIG, and plasma exchange. The discussion highlights pivotal phase 3 trials (ADAPT, MycarinG, and VIVACITY MG), evaluating differences in efficacy, dosing schedules, and administration routes for agents like efgartigimod, rozanolixizumab, and nipocalimab. Faculty discuss how data from these trials informs individualized treatment planning and facilitates shared decision-making. =

CME credits: 1.00 Valid until: 28-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-of-neuropsychiatric-symptoms-of-alzheimers-disease-early-recognition-diagnosis-and-innovative-emerging-therapies/35728/ Neuropsychiatric symptoms (NPS) associated with Alzheimer's disease (AD), such as psychosis and agitation, affect up to 50% of individuals with AD yet remain underdiagnosed and undertreated in clinical practice. These symptoms accelerate cognitive decline, increase mortality risk, and substantially worsen patient and caregiver quality of life. This broadcast replay will provide a practical and engaging discussion of the underlying pathophysiology of NPS associated with AD, the limitations of off-label antipsychotic use, and emerging therapeutic agents targeting NPS associated with AD.=

CME credits: 1.00 Valid until: 28-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-of-neuropsychiatric-symptoms-of-alzheimers-disease-early-recognition-diagnosis-and-innovative-emerging-therapies/35728/ Neuropsychiatric symptoms (NPS) associated with Alzheimer's disease (AD), such as psychosis and agitation, affect up to 50% of individuals with AD yet remain underdiagnosed and undertreated in clinical practice. These symptoms accelerate cognitive decline, increase mortality risk, and substantially worsen patient and caregiver quality of life. This broadcast replay will provide a practical and engaging discussion of the underlying pathophysiology of NPS associated with AD, the limitations of off-label antipsychotic use, and emerging therapeutic agents targeting NPS associated with AD.=

CME credits: 0.75 Valid until: 30-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/treatment-advances-in-generalized-myasthenia-gravis-a-pathophysiology-driven-framework-leveraging-fcrn-therapeutics/29537/ Traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial for many patients in the short term but often come with unacceptable side effects. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) has created a groundbreaking paradigm shift in our approach to both the short- and longer-term management of affected patients. Join Drs. Vera Bril and Neelam Goyal as they take a deep dive into this topic and discuss how FcRn inhibitors are changing the therapeutic landscape of gMG.=

CME credits: 0.75 Valid until: 30-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/treatment-advances-in-generalized-myasthenia-gravis-a-pathophysiology-driven-framework-leveraging-fcrn-therapeutics/29537/ Traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial for many patients in the short term but often come with unacceptable side effects. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) has created a groundbreaking paradigm shift in our approach to both the short- and longer-term management of affected patients. Join Drs. Vera Bril and Neelam Goyal as they take a deep dive into this topic and discuss how FcRn inhibitors are changing the therapeutic landscape of gMG.=

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/ocular-to-generalized-mg-how-and-why-the-disease-evolves/32733/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/autoantibodies-explained-anti-achr-anti-musk-and-their-diagnostic-role/32728/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnostic-advances-in-gmg-effective-tools-and-techniques/32727/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/living-with-gmg-navigating-personal-professional-and-mental-health-challenges/32726/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 0.75 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/treatment-advances-in-generalized-myasthenia-gravis-clinical-and-laboratory-criteria-for-diagnosis-and-optimal-treatment-selection/29533/ The adult and pediatric diagnostic and treatment landscapes of generalized myasthenia gravis (gMG) are both similar and different. While current traditional therapies are often effective in the short term, selecting the most appropriate short- and longer-term treatment for each patient, whether adult or pediatric, brings with it unique individual challenges. These challenges include how best to utilize newer targeted agents in the treatment of gMG, such as the neonatal Fc receptor (FcRn) inhibitors. Join Drs. Vera Bril and Jonathan Strober as they tackle these issues from both the adult and pediatric perspective.=